Moderna to Present at Upcoming Conferences in September 2025
-
Lawrence sparks Jaguars over Chiefs in NFL thriller
-
EU channels Trump with tariffs to shield steel sector
-
Labuschagne out as Renshaw returns to Australia squad for India ODIs
-
Open AI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Tokyo stocks hit new record as Asian markets extend global rally
-
Computer advances and 'invisibility cloak' vie for physics Nobel
-
Nobel literature buzz tips Swiss postmodernist, Australians for prize
-
Dodgers hold off Phillies to win MLB playoff thriller
-
China exiles in Thailand lose hope, fearing Beijing's long reach
-
Israel marks October 7 anniversary as talks held to end Gaza war
-
Indians lead drop in US university visas
-
Colombia's armed groups 'expanding,' warns watchdog
-
Shhhh! California bans noisy TV commercials
-
Trump 'happy' to work with Democrats on health care, if shutdown ends
-
Trump says may invoke Insurrection Act to deploy more troops in US
-
UNESCO board backs Egyptian for chief after US row
-
Greta Thunberg lands in Greece with expelled Gaza flotilla activists
-
Unreachable Nobel winner hiking 'off the grid'
-
Retirement or marketing gimmick? Cryptic LeBron video sets Internet buzzing
-
CAF 'absolutely confident' AFCON will go ahead in protest-hit Morocco
-
Paris stocks slide amid French political upheaval, Tokyo soars
-
EU should scrap ban on new combustion-engine sales: Merz
-
US government shutdown enters second week, no end in sight
-
World MotoGP champion Marquez to miss two races with fracture
-
Matthieu Blazy reaches for the stars in Chanel debut
-
Macron gives outgoing French PM final chance to salvage government
-
Illinois sues to block National Guard deployment in Chicago
-
Exiled Willis succeeds Dupont as Top 14 player of the season
-
Hamas and Israel open talks in Egypt under Trump's Gaza peace plan
-
Mbappe undergoing treatment for 'small niggle' at France camp: Deschamps
-
Common inhalers carry heavy climate cost, study finds
-
Madagascar president taps general for PM in bid to defuse protests
-
Greta Thunberg lands in Greece among expelled Gaza flotilla activists
-
UEFA 'reluctantly' approves European league games in US, Australia
-
Hundreds protest in Madagascar as president to announce new premier
-
Greta Thunberg lands in Greece among Gaza flotilla activists deported from Israel
-
UNESCO board backs Egyptian ex-minister for top job: official
-
Facing confidence vote, EU chief calls for unity
-
Cash-strapped UNHCR shed 5,000 jobs this year
-
Mbappe to have 'small niggle' examined at France camp: Deschamps
-
Brazil's Lula asks Trump to remove tariffs in 'friendly' phone call
-
Paris stocks slide as French PM resigns, Tokyo soars
-
'Terrible' Zverev dumped out of Shanghai by France's Rinderknech
-
What are regulatory T-cells? Nobel-winning science explained
-
Indirect talks on ending Gaza war begin in Sharm El-Sheikh: Egypt media
-
OpenAI signs multi-billion dollar chip deal with AMD
-
Salah under fire as Liverpool star loses his spark
-
Paris stocks drop as French PM resigns, Tokyo soars
-
ICC finds Sudan militia chief guilty of crimes against humanity
-
Zverev dumped out of Shanghai Masters by France's Rinderknech
NYSE - LSE
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:
Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET
Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
P.Costa--AMWN
